Scott M. Hammer

Q: What Schools Are Affiliated With Scott M. Hammer

Scott M. Hammer is affiliated with the following schools: Columbia University, University of Miami, Thomas Jefferson University, University of Pennsylvania, Harvard University

Scott M. Hammer's AcademicInfluence.com Rankings

Scott M. Hammer

Physics

#7137

World Rank

#9149

Historical Rank

physics Degrees

Download Badge

Physics

Why Is Scott M. Hammer Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Scott M. Hammer's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. (1997) (2544)
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. (2008) (2385)
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. (1997) (1316)
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. (2000) (1117)
Antiretroviral Treatment of Adult HIV Infection (2008) (1090)
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. (1996) (1011)
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. (1998) (1006)
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. (2000) (917)
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. (2008) (828)
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. (2002) (777)
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. (2006) (769)
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. (2012) (742)
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. (2004) (730)
Antiretroviral therapy for HIV infection in 1996 : Recommendations of an international panel (1996) (651)
The challenge of HIV-1 subtype diversity. (2008) (595)
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. (1998) (593)
Treatment for adult HIV infection. (2004) (580)
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. (2003) (575)
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. (2008) (569)
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. (2013) (536)
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. (1996) (502)
Multiple, Linked Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Treatment-Experienced Patients Are Missed by Standard Genotype Analysis (2005) (502)
Staphylococcus epidermidis infections. (1983) (485)
Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. (2000) (479)
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. (1996) (451)
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. (2004) (380)
The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan (2000) (364)
Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. (2001) (294)
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. (2004) (283)
Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. (1998) (252)
ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results (2001) (252)
HIV Vaccine Research: The Way Forward (2008) (250)
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. (2000) (207)
Cytomegalovirus Immune Globulin Prophylaxis in Liver Transplantation (1993) (201)
Combining Google Earth and GIS mapping technologies in a dengue surveillance system for developing countries (2009) (193)
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. (2002) (192)
INTRODUCTION TO INFECTIOUS DISEASE (2004) (187)
Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodies (2015) (179)
Host Determinants in HIV Infection and Disease: Part 2: Genetic Factors and Implications for Antiretroviral Therapeutics* (2001) (162)
Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. (1995) (153)
Cytomegalovirus Vasculitis: Case Reports and Review of the Literature (1994) (147)
Population Pharmacokinetics and Pharmacodynamics of Efavirenz, Nelfinavir, and Indinavir: Adult AIDS Clinical Trial Group Study 398 (2003) (146)
Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine (2000) (143)
Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. (2004) (139)
Zidovudine: five years later. (1992) (137)
Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. (2001) (134)
In vitro modification of human immunodeficiency virus infection by granulocyte-macrophage colony-stimulating factor and gamma interferon. (1986) (126)
Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings (2012) (125)
Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature. (2001) (124)
Activation of human immunodeficiency virus by herpes simplex virus. (1992) (119)
Treatment of Listeria monocytogenes infection with trimethoprim-sulfamethoxazole: case report and review of the literature. (1986) (117)
Host Determinants in HIV Infection and Disease: Part 1: Cellular and Humoral Immune Responses* (2001) (116)
Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission (2006) (114)
HIV fusion and its inhibition. (2001) (113)
Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients. (2010) (111)
Ebola and quarantine. (2014) (108)
Differences Between Women and Men in Adverse Events and CD4+ Responses to Nucleoside Analogue Therapy for HIV Infection (2000) (101)
Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. (2011) (97)
207-nm UV Light - A Promising Tool for Safe Low-Cost Reduction of Surgical Site Infections. I: In Vitro Studies (2013) (97)
Advances in antiretroviral therapy and viral load monitoring. (1996) (96)
The herpes simplex virus immediate-early protein, ICP4, is required to potentiate replication of human immunodeficiency virus in CD4+ lymphocytes (1989) (96)
Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. (2009) (90)
The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. The Women Infant Transmission Study Clinics. Virology Quality Assurance Program. (1999) (88)
Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis (2000) (88)
A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. (2003) (83)
Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women. (2010) (82)
Methylation of the viral genome in an in vitro model of herpes simplex virus latency. (1982) (82)
Synergistic activity of granulocyte-macrophage colony-stimulating factor and 3'-azido-3'-deoxythymidine against human immunodeficiency virus in vitro (1987) (82)
Parasitic sinusitis and otitis in patients infected with human immunodeficiency virus: report of five cases and review. (1997) (81)
GANCICLOVIR THERAPY OF SEVERE CYTOMEGALOVIRUS INFECTIONS IN SOLID‐ORGAN TRANSPLANT RECIPIENTS (1988) (79)
Management of Newly Diagnosed HIV Infection (2005) (78)
Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. (2014) (77)
Predictors of Virologic and Clinical Outcomes in HIV-1Infected Patients Receiving Concurrent Treatment with Indinavir, Zidovudine, and Lamivudine: AIDS Clinical Trials Group Protocol 320 (2001) (75)
Pulmonary complications of orthotopic liver transplantation. (1986) (74)
Measuring quality of life in early HIV disease: the modular approach (1997) (73)
Advances in antiretroviral therapy. (2009) (71)
Inactivation of human immunodeficiency virus by Betadine products and chlorhexidine. (1989) (68)
Comparison of Two Indinavir/Ritonavir Regimens in the Treatment of HIV-Infected Individuals (2004) (67)
Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. (2019) (66)
Patterns of geographic mobility predict barriers to engagement in HIV care and antiretroviral treatment adherence. (2014) (65)
Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011. (2012) (64)
What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials. (2003) (61)
Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group (1994) (61)
Clinical trials using HIV-1 RNA-based primary endpoints: statistical analysis and potential biases. (1999) (61)
Use of virologic assays for detection of human immunodeficiency virus in clinical trials: recommendations of the AIDS Clinical Trials Group Virology Committee (1993) (61)
Frequent identification of HIV-1 DNA in bronchoalveolar lavage cells obtained from individuals with the acquired immunodeficiency syndrome. (1991) (59)
Vitamin D deficiency in HIV-infected postmenopausal Hispanic and African-American women (2011) (59)
Neuromuscular function in HIV infection: analysis of a placebo‐controlled combination antiretroviral trial (1998) (59)
The extent of non‐adherence in a large AIDS clinical trial using plasma dideoxynucleoside concentrations as a marker (1998) (58)
Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team. (2000) (58)
Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial (2017) (57)
Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120. (1998) (56)
Effect of Ex Vivo–Expanded Recipient Regulatory T Cells on Hematopoietic Chimerism and Kidney Allograft Tolerance Across MHC Barriers in Cynomolgus Macaques (2017) (56)
Shifts to and from Daylight Saving Time and Incidence of Myocardial Infarction (2008) (54)
Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy. (2001) (53)
Effect of zidovudine and granulocyte-macrophage colony-stimulating factor on human immunodeficiency virus replication in alveolar macrophages. (1990) (53)
Antiretroviral treatment as prevention. (2011) (50)
Variability and Prognostic Values of Virologic and CD4 Cell Measures in Human Immunodeficiency Virus Type 1‐Infected Patients with 200–500 CD4 Cells/mm3(ACTG 175) (1998) (50)
Epstein-Barr virus-induced infectious mononucleosis complicated by acute renal failure: case report and review. (1996) (49)
Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy. (2003) (49)
The pathophysiology of enhanced susceptibility to murine cytomegalovirus respiratory infection during short-term exposure to 5 ppm nitrogen dioxide. (1988) (49)
The acute aseptic meningitis syndrome. (1990) (47)
Antiretroviral therapy: reverse transcriptase inhibition (1992) (47)
Temporal cluster of herpes simplex encephalitis: investigation by restriction endonuclease cleavage of viral DNA. (1980) (47)
Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120 (2017) (45)
The challenge of HIV-1 subtype diversity. (2008) (45)
Virologic and regimen termination surrogate end points in AIDS clinical trials. (2001) (45)
Metabolic Complications in HIV-1 Infection: Summary of Selected Trials (2002) (44)
Preventing HIV-1 Infection in Women using Oral Pre-Exposure Prophylaxis: A Meta-analysis of Current Evidence. (2016) (43)
Didanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay (1992) (43)
Both serum HIV type 1 RNA levels and CD4+ lymphocyte counts predict clinical outcome in HIV type 1-infected subjects with 200 to 500 CD4+ cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. (2000) (41)
C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s (2004) (40)
A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens (2011) (40)
Pre-Existing Adenovirus Immunity Modifies a Complex Mixed Th1 and Th2 Cytokine Response to an Ad5/HIV-1 Vaccine Candidate in Humans (2011) (40)
Physiological effects of HIV infection on human intestinal epithelial cells: an in vitro model for HIV enteropathy (1994) (39)
Determination of Clinically Relevant Cutoffs for HIV-1 Phenotypic Resistance Estimates Through a Combined Analysis of Clinical Trial and Cohort Data (2008) (37)
Immunologic markers as predictors of tuberculosis-associated immune reconstitution inflammatory syndrome in HIV and tuberculosis coinfected persons in Thailand. (2009) (37)
Antiretroviral treatment for HIV infection in developing countries: an attainable new paradigm (2003) (37)
HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients (2002) (36)
Acceptability of male circumcision for the prevention of HIV among high-risk heterosexual men in Thailand. (2010) (34)
Activation and suppression of herpes simplex virus in a human T lymphoid cell line. (1981) (34)
Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine. (2004) (33)
Clinical practice. Management of newly diagnosed HIV infection. (2005) (33)
Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy. (2001) (32)
Increasing choices for HIV therapy. (2002) (31)
Incidence of Diabetes Mellitus and Obesity and the Overlap of Comorbidities in HIV+ Hispanics Initiating Antiretroviral Therapy (2016) (31)
Single-dose nevirapine and drug resistance: the more you look, the more you find. (2005) (31)
Brief Report: Preventing HIV-1 Infection in Women Using Oral Preexposure Prophylaxis: A Meta-analysis of Current Evidence. (2016) (30)
Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir (2002) (28)
Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial (2018) (28)
Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition (1992) (27)
Effects of recombinant soluble CD4 (rCD4) on HIV-1 infection of monocyte/macrophages. (1990) (26)
Lack of in vivo effect of granulocyte-macrophage colony-stimulating factor on human immunodeficiency virus type 1. (1996) (26)
Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials (2015) (25)
Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team. (1998) (25)
[The antiretroviral agents]. (1998) (25)
Serologic diagnosis of focal pneumonia caused by Cryptococcus neoformans. (1985) (24)
Antiretroviral therapy: where are we? (1998) (24)
Potent inhibition of human immunodeficiency virus type 1 in primary T cells and alveolar macrophages by a combination anti-Rev strategy delivered in an adeno-associated virus vector (1997) (23)
Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083. (2016) (23)
Diarrheal disease in patients infected with human immunodeficiency virus in Bangkok, Thailand. (1999) (23)
Pharmacokinetics of F105, a human monoclonal antibody, in persons infected with human immunodeficiency virus type 1 (1996) (23)
Herpes simplex virus infection of human T-cell subpopulations (1982) (22)
Issues in combination antiretroviral therapy: a review. (1994) (22)
HTLV-III/LAV infection in kidney and liver transplantation. (1987) (22)
Alpha interferon and acyclovir treatment of herpes simplex virus in lymphoid cell cultures (1982) (22)
Antiretroviral Resistance Testing Comes of Age (2000) (22)
The values of quantitative serum HIV-1 RNA levels and CD4 cell counts for predicting survival time among HIV-positive individuals with CD4 counts of ⩽ 50 × 106 cells/l (2000) (22)
Intentions to Use Preexposure Prophylaxis Among Current Phase 2B Preventive HIV-1 Vaccine Efficacy Trial Participants (2013) (21)
Transmitted drug resistance among antiretroviral-naive patients with established HIV type 1 infection in Santo Domingo, Dominican Republic and review of the Latin American and Caribbean literature. (2012) (21)
The DAD Study Group. Combination antiretroviral therapy and the risk of myocardial infarction (2003) (21)
Immune Activation While on Potent Antiretroviral Therapy Can Predict Subsequent CD4+ T-Cell Increases Through 15 Years of Treatment (2013) (20)
Patents versus patients? Antiretroviral therapy in India. (2005) (20)
Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial (2019) (20)
Amdoxovir versus Placebo with Enfuvirtide plus Optimized Background Therapy for HIV-1-Infected Subjects Failing Current Therapy (Aactg A5118) (2005) (20)
Potent Inhibition of Human Immunodeficiency Virus Type 1 in Primary T Cells and Alveolar Macrophages by a Combination Anti-Rev Strategy Delivered in an Adeno-Associated Virus Vector (1998) (19)
Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults. (2010) (19)
Indinavir, Efavirenz, and Abacavir Pharmacokinetics in Human Immunodeficiency Virus-Infected Subjects (2003) (19)
In pursuit of an HIV vaccine: designing efficacy trials in the context of partially effective nonvaccine prevention modalities. (2013) (19)
Infectious complications with the use of cyclosporine versus azathioprine after cadaveric kidney transplantation. (1987) (18)
Association of Efavirenz Hypersusceptibility with Virologic Response in ACTG 368, a Randomized Trial of Abacavir (ABC) in Combination with Efavirenz (EFV) and Indinavir (IDV) in HIV-Infected Subjects with Prior Nucleoside Analog Experience (2008) (18)
Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine. (2004) (18)
Lessons Drawn From Recent HIV Vaccine Efficacy Trials (2010) (17)
Changes in Hepatitis C Virus (HCV) Viral Load and Interferon-&agr; Levels in HIV/HCV-Coinfected Patients Treated With Highly Active Antiretroviral Therapy (2006) (17)
Emerging infections 8. (2008) (17)
Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm(3) (ACTG 175). AIDS Clinical Trials Group Protocol 175 Team. (1998) (16)
Pathogenicity and diversity of HIV and implications for clinical management: a review. (1994) (16)
Zidovudine (AZT) Monotherapy Selects for the A360V Mutation in the Connection Domain of HIV-1 Reverse Transcriptase (2012) (15)
Comparing Interferon-Gamma Release Assays to Tuberculin Skin Test in Thai Children with Tuberculosis Exposure (2014) (15)
Antiretroviral guidelines for resource-limited settings: The WHO's public health approach (2002) (15)
In vivo effects of interleukin 3 in HIV type 1-infected patients with cytopenia. (1995) (15)
Comparison of gynecologic history and laboratory results in HIV-positive women with CD4+ lymphocyte counts between 200 and 500 cells/μl and below 100 cells/μl (1999) (15)
A Randomized Trial of Nelfinavir and Abacavir in Combination with Efavirenz and Adefovir Dipivoxil in HIV-1-Infected Persons with Virological Failure Receiving Indinavir (2002) (13)
Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS? (2016) (13)
Advances in antiretroviral therapy. (2005) (13)
Detection of Replication-Competent Human Immunodeficiency Virus Type 1 (HIV-1) in Cultures from Patients with Levels of HIV-1 RNA in Plasma Suppressed to Less Than 500 or 50 Copies Per Milliliter (2002) (13)
Virologic and CD4+ cell responses to new nucleoside regimens: switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection. ACTG 302 Study Team. AIDS Clinical Trials Group. (2000) (12)
Advances in antiretroviral therapy. (2007) (12)
Advances in antiretroviral therapy. (2007) (12)
Antiviral Therapy for HIV Infection (1997) (11)
The relationship between genotypic sensitivity score and treatment outcomes in late stage HIV disease after supervised HAART (2009) (11)
Testing the waters: Ethical considerations for including PrEP in a phase IIb HIV vaccine efficacy trial (2015) (10)
Perspective: human immunodeficiency virus type 1 (HIV-1) RNA end points in HIV clinical trials: issues in interim monitoring and early stopping. (1998) (10)
A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen. (2010) (10)
CROI 2013: Advances in antiretroviral therapy. (2013) (10)
Ganciclovir Hepatotoxicity (1987) (10)
Poor agreement between 2 assays for measuring low levels of HIV-1 viral load. (2009) (9)
Antiherpesvirus, Anti-Hepatitis Virus, and Anti-Respiratory Virus Agents (2009) (9)
HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388. (2004) (9)
Baby steps on the road to HIV eradication. (2013) (9)
Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1-Uninfected Adult Participants (2014) (9)
Low Frequency NNRTI-Resistant Variants Contribute to Failure of Efavirenz-Containing Regimens in Treatment-Experienced Patients (2010) (8)
Infiltration of the lower respiratory tract by helper/inducer T lymphocytes in HTLV-1-associated adult T-cell leukemia/lymphoma. (1991) (8)
Evaluation of an infectivity standard for real-time quality control of human immunodeficiency virus type 1 quantitative micrococulture assays. Participating Laboratories of The AIDS Clinical Trials Group (1996) (8)
A comparison of two dosing regimens of zidovudine in Thai adults with early symptomatic HIV infection. Conducting clinical HIV trials in South-East Asia. (2000) (8)
A Randomized, Placebo-Controlled Trial of Abacavir Intensification in HIV-1–Infected Adults With Virologic Suppression on a Protease Inhibitor–Containing Regimen (2010) (7)
ISOLATION OF HUMAN IMMUNODEFICIENCY VIRUS AND SERUM NEUTRALISING ANTIBODY (1986) (7)
Viral aseptic meningitis in the United States: clinical features, viral etiologies, and differential diagnosis. (1992) (7)
Translational Research Insights From Completed HIV Vaccine Efficacy Trials (2013) (7)
Effect of the calcium channel blocker verapamil on human immunodeficiency virus type 1 replication in lymphoid cells. (1991) (7)
Advances in antiretroviral therapy. (2003) (7)
Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine. (2000) (6)
The Global HIV Drug Resistance Surveillance Program: a partnership between WHO and IAS. International AIDS Society. (2002) (6)
HIV Drug Resistance: Implications for Management. (2002) (6)
AZT trial in Thailand. (1995) (6)
Comparison of gynecologic history and laboratory results in HIV-positive women with CD4+ lymphocyte counts between 200 and 500 cells/microl and below 100 cells/microl. (1999) (5)
Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: combination therapy. (1992) (5)
HIV‐1 Tat modulates invasion by a bacterial enteric pathogen into a human intestinal cell line (1995) (5)
Nucleoside analogue reverse transcriptase inhibitor options: a re-examination of the class. (2006) (5)
Infusion phlebitis associated with a programmable syringe-pump system versus gravity-feed minibottles. (1987) (5)
Letter to the editor of the NEJM (1998) (5)
Herpes simplex virus replication in interleukin-2-stimulated human T cells. (1985) (5)
Rectal and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge. (2021) (4)
Virologic and CD4 cell response to zidovudine or zidovudine and lamivudine following didanosine treatment of human immunodeficiency virus infection. (2001) (4)
Efficient trial designs for studying combination antiretroviral treatments in patients with various resistance profiles. (1998) (4)
Effects of recombinant interleukin-2 on resting human T lymphocytes. (1986) (4)
Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge (2021) (4)
Study and laboratories participating in The Virology Quality Assurance Program. (1999). The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements (1999) (3)
Acyclovir‐Associated Fever: A Case Report (1987) (3)
Antiretroviral and immune-based therapies: update. (1993) (3)
Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individuals. (1997) (3)
Stabilities of free and complexed human immunodeficiency virus p24 antigens during short- and long-term storage (1997) (3)
Assessing Knowledge of HIV Vaccines and Biomedical Prevention Methods Among Transgender Women in the New York City Tri-State Area (2020) (2)
Dideoxynucleoside Resistance Emerges with Prolonged Zidovudine Monotherapy (2003) (2)
Highlights of the 15th Conference on Retroviruses and Opportunistic Infections. Advances in antiretroviral therapy. (2008) (2)
The association of α4β7 expression with HIV acquisition and disease progression in people who inject drugs and men who have sex with men: Case control studies (2020) (2)
Virologic and CD 4 1 Cell Responses to New Nucleoside Regimens : Switching to Stavudine or Adding Lamivudine after Prolonged Zidovudine Treatment of Human Immunodeficiency Virus Infection (2004) (2)
Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines Panel. (2003) (2)
World Health Organization Public Health Approaches to Expand Antiretroviral Treatment Public Health Approaches to Expand Antiretroviral Treatment (2003) (2)
A markov model for the effect of covariates including drug adherence on longitudinal viral response in hiv patients (2004) (2)
In vitro modification of human immunodeficiency virus infection by granulocyte-macrophage colony-stimulating factor and y interferon ( U-937 cells ) (1999) (1)
Staphylococcal Pyomyositis in Liver Transplantation: Case Report and Review (1995) (1)
Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial (2012) (1)
Registry—Acquired Immunodeficiency Syndrome and Clinical Transplantation (1987) (1)
Use of Surrogate versus Clinical Markers in Trials for HIV Infection (1999) (1)
MINIREVIEW Antiretroviral Therapy: Reverse Transcriptase Inhibition (1992) (1)
Management of Antiretroviral Therapy (2002) (1)
Recommendations of the International AIDS Antiretroviral Treatment of Adult HIV Infection : 2008 (2008) (1)
Cornell/amfAR Symposium. Strategies of antiretroviral therapy. (2002) (1)
Advances in antiretroviral therapy. Highlights of the 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004, San Francisco, California, USA. (2004) (1)
Epidemic emergence of Chikungunya virus: options for control of an enzootic virus. (2008) (1)
Infectious Complications With the Use of Cyclosporine Versus Azathioprine After Cadaveric Kidney Transplantation (1987) (0)
AZT trials to reduce perinatal HIV transmission: a debate about science ethics and resources. Roundtable. Letter to the editor of the NEJM. (1998) (0)
Treatment of HIV infection: the antiretroviral nucleoside analogues. Introduction. (1992) (0)
Treatment Approaches and Clinical Parameters Predictive of CMV Disease and Resolution in Immunodeficient Cynomolgus Macaques – a Clinically Relevant Large Animal Model (2016) (0)
Speci ﬁ city and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modi ﬁ ed Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles (2014) (0)
New Antiretrovirals in Development: The View in 2002 (2002) (0)
Antirespiratory Virus Agents (2017) (0)
Ethics of placebo-controlled trials of zidovudine to prevent the perinatal transmission of HIV in the Third World. (1998) (0)
Advances in antiretroviral therapy. (2010) (0)
Chapter 145 – Antiretroviral agents (2010) (0)
Immunosuppressive Effect of Zidovudine (1993) (0)
Psychosocial aspects of HIV treatment. Author's reply (2007) (0)
HIV-1 Resistance in Supervised Treatment Settings (2008) (0)
Psychosocial Aspects of HIV Treatment—Reply (2007) (0)
an in vitro model of herpes (2016) (0)
Antiretroviral Therapy Update (2000) (0)
Advances in antiretroviral therapy. (2011) (0)
Evaluation of an infectivity standard for real time quality control of HIV-1 quantitative microculture assays (1996) (0)
Alpha Interferon and Acyclovir Treatment of Herpes Simplex Virus in Lymphoid Cell Cultures (1982) (0)
To treat or not to treat--approaches to antiretroviral therapy. Interview by Anthony J. Japour. (1996) (0)
I. New Nucleoside/Nucleotide Analogues (2003) (0)
An approach to antiretroviral treatment of HIV disease. Nucleoside monotherapy. (1995) (0)
Advances in Preventive Vaccines (2015) (0)
Anti–Hepatitis Virus Agents (2017) (0)
Advances in HIV Pathogenesis (2008) (0)
Advances in antiretroviral therapy. (2006) (0)
Erratum: Potent inhibition of human immunodeficiency virus type 1 in primary T cells and alveolar macrophages by a combination anti-Rev strategy delivered in an adeno-associated virus vector (Journal of Virology 71:5 (4071-4078)) (1998) (0)
Human T-lymphotropic virus type III infection in previously immunocompromised hosts. (1986) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Scott M. Hammer?

Scott M. Hammer is affiliated with the following schools:

Scott M. Hammer's Academic­Influence.com Rankings

Why Is Scott M. Hammer Influential?

Scott M. Hammer's Published Works

Published Works

What Schools Are Affiliated With Scott M. Hammer?

Scott M. Hammer's AcademicInfluence.com Rankings